Stem Cell Clinic

BioCardia Announces Issuance of Two Patents Related to … – BioSpace

By Stell Cell Research

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.

The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled Multi-Directional Steerable Catheter, with a patent term that will expire in 2035. The patent claims a fundamental design for steerable introducer sheaths, such as those used for BioCardias autologous and allogeneic cell therapy procedures, and for transseptal procedures for the treatment of cardiac arrhythmias. The design enables the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction. This design is intended to enable smooth navigation and prevent whip, when a catheter in the heart suddenly jumps from one orientation to another due to the build-up of mechanical forces in the device. This patented design is incorporated in the Companys FDA-cleared Morph DNA product, a 5 French sheath equivalent, and in the Companys FDA-cleared Avance product, an 8.5 French introducer sheath indicated for transseptal procedures.

The Indian Patent Office granted the Company Patent Number 424579, entitled Steerable Endoluminal Devices and Methods for Use, with a patent term that will expire in late 2031. The patent claims a fundamental design for steerable introducer sheaths. The design is for a coil with a braid disposed coaxially about the coil, all embedded within the wall of an introducer sheath. The coil enables a robust, kink-resistant design with enhanced column support, while the braid in the catheter shaft provides for excellent torque transmission. This patent design feature has demonstrated excellent performance in the Companys Morph Access Pro product family and has been used to treat approximately 10,000 patients to-date, ranging from a two-year-old girl to a 90-year-old man.

This positive experience with the Morph DNA, Avance, and Morph AccessPro underlies our understanding of catheter navigation that informs the delivery of our higher-value biotherapeutic interventions, where we utilize steerable guide sheaths in every procedure, said BioCardia CEO Peter Altman, PhD. The acquisitions of Baylis by Boston Scientific for $1.5 billion and the acquisition of the Acutus sheath portfolio by Medtronic for $87 million last year were focused on enabling transseptal access devices, like these, that enable ablation therapies to treat cardiac arrhythmias. These acquisitions show that these steerable catheter assets are nontrivial to develop and that the intellectual property that underlies these assets has the potential to enable large market opportunities and be quite valuable.

These new patents are anticipated to strengthen the protection of BioCardias efforts with respect to its cardiovascular therapeutic approaches and provide enhanced value for all therapies developed with the Helix biotherapeutic delivery system product family.

ABOUT BIOCARDIABioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic platforms that enable four product candidates in development. The CardiAMP Cell Therapy Heart Failure Trial investigational product has been granted Breakthrough designation by the FDA, has CMS reimbursement, and is supported financially by the Maryland Stem Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial also has CMS Reimbursement. The Company's current products include the Helix Transendocardial Biotherapeutic Delivery System, which it partners selectively with other biotherapeutic companies requiring local delivery to the heart. For more information visit:www.BioCardia.com.

FORWARD LOOKING STATEMENTSThis press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to development and value of steerable access catheter products and intellectual property and statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans, the ability to enter into licensing and partnering arrangements, and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Anne Laluc, MarketingEmail:alaluc@BioCardia.comPhone: 650-226-0120

Investor Contact: David McClung, Chief Financial OfficerEmail:investors@BioCardia.comPhone: 650-226-0120

The rest is here:
BioCardia Announces Issuance of Two Patents Related to ... - BioSpace

Dr. Narine Sarvazyan Has Been Named to the AUA William Frazer Endowed Professorship – Armenian News by MassisPost

By Stell Cell Research

YEREVAN The American University of Armenia (AUA) is pleased to announce that Dr. Narine Sarvazyan has been named to the AUAWilliam Frazer Endowed Professorship. Endowed by AUA Trustee Emeritus and longtime benefactor Edward Avedisian, this professorship was created in honor of Professor William Frazer, University of California (UC) Provost and Senior Vice President Emeritus, Academic Affairs, and Professor Emeritus, UC Berkeley Department of Physics. Dr. Frazer served as the inaugural Chairman of the Board of AUA Corporation, UC Provost and Senior Vice President of Academic Affairs, Acting Provost of UC San Diegos Third College, and research scientist at the Institute for Advanced Study, Princeton, New Jersey.

Dr. Sarvazyan started her career at Moscow State University, where she received her bachelors and masters degrees in physics and biophysics, respectively, and later joined the Yerevan Institute of Experimental Biology (now called the Institute of Molecular Biology NAS RA), where she received a Ph.D. in biological sciences. Within a few months after defending her dissertation, she left Armenia to pursue postdoctoral research first in Europe and later in the United States. She then joined the faculty of Texas Tech University Health Science Center, followed by her appointment as a tenured professor at the George Washington (GW) University School of Medicine and Health Sciences, where she led an interdisciplinary program at the intersection of medicine, physics, and engineering.

Dr. Sarvazyans research interests range from free-radical-mediated cardiotoxicity of anticancer drugs to the adverse effects of plasticizers, hyperspectral imaging, novel medical devices, stem cell therapy, 3D bioprinting, and tissue engineering. Her scientific discoveries have been published in several prestigious journals, includingNature, Journal of Clinical Investigation, Tissue Engineering, Stem Cell Reviews, Circulation, PLoS One, American Journal of Physiology,among others. She is the recipient of a number of prestigious research and teaching awards, and has repeatedly received funding from the U.S. National Institutes of Health, the National Science Foundation, and the American Heart Association.

Asked what initially led her to her profession, Dr. Sarvazyan remarks that the decision came naturally. Raised in Pushchino, Russia, a center of biological science back in the Soviet era, she was interested in science from early childhood years. My father led a lab in biophysical acoustics, so from early childhood, I was exposed to science, she recalls, I used to visit his lab, which was a very natural environment for me to be in. I never once regretted my decision. I love what I do.

Professor of pharmacology and physiology, Dr. Sarvazyan likes challenges. Science is always a challenge because you have a hypothesis, you try, and in 90% of the cases, you are not right. So you have to pivot all the time to find answers, she says, adding, Nowadays, with the mass involvement of hundreds of thousands of people in science and technology, just finding those niches where you can make a difference is itself a challenge. Thats challenge number one. Challenge number two is getting funding for pursuing your ideas. And then comes challenge number three, that is, to actually discover something new. All these challenges are difficult to solve, but they are also inspiring, and I love to solve them.

Dr. Sarvazyan has joined AUA to bring her expertise in research and education to Armenia. Under her leadership, the University is planning to establish the Akian BioScience Laboratory. Dr. Sarvazyan is currently based at the Akian College of Science and Engineering, and starting Fall 2023, she will be introducing new hands-on courses focusing on biomedical research. The classes will be limited to 10-12 students because all of them will be project-based and will involve supervised experimentation. She is excited to start working with AUA students, who she believes possess great potential and curiosity, I encourage those interested in biomedical research to contact me directly or come to my office to talk because enrollment will be very limited, she adds.

Having founded and leading a lab, Dr. Sarvazyan has been engaged in a variety of research projects. Her team at the Sarvazyan Lab at GW School of Medicine and Health Sciences works at the intersection of biology, physiology, physics, and instrumentation. I have always had students from different professional backgrounds and walks of life, which has enhanced the interaction among them because everyone has learned something from someone else. I hope to create a similar environment here, she says.

Science is not easy: you have to be ready to fail many times and still have enough energy and excitement to keep going, so you can get your experiments working, Dr. Sarvazyan remarks. She believes that only by actually doing something with their hands in the lab students can discover their passion for experimental science. She looks forward to starting such a hands-on classroom. Students learn much better through trial and error and by doing things with their hands. And based on my experience, that is what they also enjoy the most.

Dr. Sarvazyan is positive about the future of science in Armenia. She cautions that the resources needed to conduct competitive biomedical science are enormous, but with strong commitment of the government, local businesses, and the diaspora, she believes, it is possible to create the right environment. We can start by creating regional biomedical research centers to fill in the gaps its not an easy task, but its doable. Its important to first identify the areas where we can be competitive and start to build on it. What I currently have in mind is hyperspectral imaging technology, which I believe is a very promising tool for many medical applications. This is just one of the projects I would like to implement here. It is a relatively new direction and I think its possible to make it successful in Armenia, she elaborates.

Successful in her academic and professional career, Dr. Sarvazyan considers balancing family and academic career to be her most outstanding accomplishment. The fact that I managed to stay married for 40 years and raised two successful children while creating a research environment that helped many outstanding students achieve their career goals I think its a pretty good accomplishment, she smiles.

Apart from sharing her professional expertise with AUA students, Dr. Sarvazyan, together with her husband, Dr. Artur Petrosian, AUAs former Computer Science department chair, also have financially invested in education they areAUA pillars. We have always felt a strong connection with Armenia. We both believe that science, education, and research are what make a country stronger. I think many people would agree that AUA does a great job educating the new generation of Armenian youth. We believe that this institution really can benefit from our input and investment. By giving back to Armenia, were investing in our future, she remarks.

Go here to read the rest:
Dr. Narine Sarvazyan Has Been Named to the AUA William Frazer Endowed Professorship - Armenian News by MassisPost

BrainStorm Cell Therapeutics Announces Full Year 2022 Financial … – PR Newswire

By Stell Cell Research

Biologics License Application for NurOwn for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting

Conference call and webcast at 8:00 a.m. Eastern Time today

NEW YORK, March 30, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022 and provided a corporate update.

"Our priority in 2023 is to advance NurOwn through the regulatory process as expeditiously as possible, including making preparations for our upcoming Advisory Committee Meeting," said BrainStorm's President and Chief Executive Officer (CEO) Chaim Lebovits and Co-CEO Dr. StacyLindborg in a joint statement. "The ADCOM will provide an invaluable opportunity for an open and thoughtful discussion among BrainStorm, regulators, ALS experts, and other key stakeholders on both the urgent need for new ALS therapies and the robust and intricate dataset that we believe supports NurOwn's approval. As we move towards this important event, our clinical trial results and experienced team give us confidence in our ability to secure a successful outcome and execute on our mission of improving the lives of individuals with ALS."

Fourth Quarter 2022 and Recent Highlights

U.S. Food and Drug Administration (FDA) notified BrainStorm in a written communication that the Agency will hold an Advisory Committee Meeting (ADCOM) to review the company's Biologics License Application (BLA) for NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).

Financial Results for the Year Ended December 31, 2022

Cash, cash equivalents, and short-term bank deposits were approximately $3 million as of December 31, 2022, compared to $22 million as of December 31, 2021.

Research and development expenses for the twelve months ended December 31, 2022, and 2021 were approximately $14 million and $15.2 million, respectively.

General and administrative expenses for the twelve months ended December 31, 2022, and 2021 were approximately $10.9 million and $9.3 million, respectively.

Net loss for the twelve months ended December 31, 2022, was approximately $24.3 million, as compared to a net loss of approximately $24.5 million for the twelve months ended December 31, 2021.

Net loss per share for the twelve months ended December 31, 2022, and 2021 was $0.66 and $0.68, respectively.

Conference Call and Webcast

March 30, 2023, at 8:00 a.m. Eastern Time

Participant Numbers:Toll Free: 877-545-0523International: 973-528-0016Entry Code: 943129

Webcast URL: https://bit.ly/40EuACf

Those interested in listening to the conference call live via the internet may do so by using the webcast link above or by visiting the "Investors & Media" page of BrainStorm's website athttps://ir.brainstorm-cell.com/events-and-presentationsand clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Numbers:

Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 47908

About NurOwn

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

BrainStorm filed the BLA for ALS on September 9, 2022. BrainStorm received a Refusal to File letter from FDA on November 8, 2022, and requested a Type A meeting on December 9, 2022, which was held on January 11, 2023. The perspective shared by the FDA review team reflected what was in the previously issued RTF letter. Conversations with the FDA continued, following the Type A meeting, on the best pathway to resolve the outstanding questions that remained. During these discussions, BrainStorm was presented with multiple options to return the BLA to regulatory review, which included the regulatory procedure to File over Protest. With the commitment by FDA to accept amendments that were filed to address items raised in the FTF letter, BrainStorm notified the FDA on February 6, 2023 of our decision to request the FDA to file the NurOwn BLA for ALS over Protest.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding BrainStorm's Type A meeting with the FDAandthe clinical development of NurOwnas a therapy for the treatment of ALS, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "intend," "should," "could," "will," "believe," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, the impacts of the COVID-19 pandemic on our clinical trials, supply chain, and operations, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

Investor Relations:John MullalyLifeSci Advisors, LLCPhone: +1 617-429-3548 [emailprotected]

Media:Lisa Guiterman[emailprotected]

BRAINSTORM CELL THERAPEUTICSINC.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

(Except share data)

December31,

2022

2021

U.S.$inthousands

ASSETS

Current Assets:

Cash and cash equivalents

$

772

$

18,856

Short-term deposit (Note8)

2,211

3,238

Other accounts receivable

91

86

Prepaid expenses and other current assets (Note 4)

32

1,100

Total current assets

$

3,106

$

23,280

Long-Term Assets:

Prepaid expenses and other long-term assets

$

23

$

27

Operating lease right of use asset (Note 5)

4,389

4,781

Property and Equipment, Net (Note 6)

933

1,189

Total Long-Term Assets

$

5,345

$

5,997

Total assets

$

8,451

$

29,277

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities:

Accounts payables

$

6,224

$

3,700

Accrued expenses

84

83

Operating lease liability (Note 5)

1,427

1,461

Other accounts payables

1,065

1,073

Total current liabilities

$

8,800

The rest is here:
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial ... - PR Newswire

Celebrating Oncology Nursing Day – Hamilton Health Sciences

By Stell Cell Research

April 4 is Oncology Nursing Day, and this years theme is Oncology Nursing: Strength Within.

Our patients are wonderful people, and so appreciative. They fill my cup.

It takes a special kind of person to work in cancer care. In celebration of Oncology Nursing Day on April 4, were pleased to introduce you to five Hamilton Health Sciences (HHS) oncology nurses from our Juravinski Hospital and Cancer Centre (JHCC).

Our JHCC is the only hospital in the region where patients can be treated for all forms of cancer, with more than 26,000 cancer patients supported each year.

Tracey Mullen

Registered nurse Tracey Mullen is an oncology nurse case manager who coordinates care for patients of two malignant hematologists. (Malignant hematologists are doctors who specialize in caring for blood cancer patients.)

These case managers work as a team with doctors to support patients who are visiting for appointments at diagnosis, and during and after their cancer treatment.

The case manager assesses and updates information from the patient to share with the doctor. This can include medication changes, new symptoms, and treatment side effects such as nausea from chemotherapy.

Im usually the first face they see before meeting with their doctor, says Mullen.

Oncology nursing can be quite complex, since cancer patients may have other health and social issues that need to be considered when planning and delivering their treatment, says Mullen. We have to apply all of our nursing knowledge, including understanding how cancer treatment plans might affect other health conditions.

Mullen especially enjoys developing relationships with patients and their families. Our patients are wonderful people, and so appreciative. They fill my cup.

Ewa Sawicki

Diane Boyd

Registered nurse Diane Boyd and registered practical nurse Ewa Sawicki are bedside nurses who care for patients admitted to hospital. Boyd cares for blood cancer patients while Sawicki supports patients who are recovering from surgery for cancers including include colon, breast, liver, gynecological and urologic.

After 25 years of dealing with cancer patients, working directly with patients at the bedside has always been the job Ive enjoyed the most, says Boyd, who joined the hematology team just over a year ago. Prior to this, Boyd worked in other areas of cancer care including the chemotherapy suite, and as an oncology nurse case manager.

While cancer is a frightening word, its not all doom and gloom, adds Boyd. In hematology, especially right now with all of the research, advancements and new treatment options, we can give many patients much more hope.

Boyd also welcomes opportunities to mentor new nurses. I really enjoy working with young nurses who are so keen on learning. They inspire me with their excitement and they keep me young.

Sawicki is also passionate about bedside care. When people think of oncology, they think of chemotherapy and radiation, she says. However, many oncology patients have to undergo extensive surgeries that leave them with new wounds, ostomies, or drains that they must learn to manage. I love being a nurse and supporting them in this learning.

Megan Mantel

Registered nurse Megan Mantel is a nurse transplant coordinator, working with hematology patients needing an allogeneic stem cell transplant. An allogeneic transplant refers to stem cells from a donor.

The donor could be a family member, or someone living halfway around the world, says Mantel, who uses a worldwide database to search for the best possible match.

Mantel also supports patients in the weeks leading up to their transplant, so they know what to expect and can take all the necessary steps and tests to prepare.

Our JHCC is a top hospital in Canada for hematology, with one of the largest hematology divisions in the country. Hamilton is also a national leader in terms of stem cell transplants and cellular therapy.

Hematology is an ever-evolving area of cancer care, says Mantel. There have been so many advances in recent years, which is very motivating to me as an oncology nurse. Theres always something new to learn, and something new to offer to our patients.

Fatima Chuong

Registered nurse Fatima Chuong works with blood cancer patients visiting the hospital for day treatments including CAR-T cell therapy, plasma exchange, as well as stem cell collections and transplants.

A nurse for seven years, she discovered a passion for oncology back when she was a nursing student doing her placement at JHCC. I was really inspired by the nurses, and the care and comfort they provided to patients, says Chuong, who finds working in hematology fascinating due to rapid advancements in hematologic cancer care.

But the greatest feeling, hands-down, is hearing from blood cancer patients who got their lives back thanks to the care they received at JHCC, says Chuong.

We sometimes receive updates and photos from former patients, letting us know what theyve been doing since they left the hospital. Learning how theyve gone on to lead their best lives is so inspiring. Its absolutely the best part about being a nurse, and its the greatest feeling in the world.

Visit link:
Celebrating Oncology Nursing Day - Hamilton Health Sciences

UM Today | Faculty of Graduate Studies | 3MT winner is full of heart – UM Today

By Stell Cell Research

April 3, 2023

Keshav Narayan Alagarsamy, a PhD candidate in the department of physiology and pathophysiology at Max Rady College of Medicine, won first place at UMs Three Minute Thesis (3MT) final on March 30.

He was chosen from a group of 12 finalists in a competition that challenges graduate students to summarize their thesis in just three minutes. The goal is to effectively communicate complex research to a non-specialized audience in an engaging manner.

Passionate about the ability of machines and materials to heal humans, Alagarsamy is combining stem cell technology with nanotechnology to create personalised heart cells that can regenerate a damaged heart after a heart attack.

One of the most rewarding aspects of my 3MT experience was the exhilarating challenge of delivering a flawless presentation despite experiencing nerves on multiple occasions, explains Alagarsamy.

This journey played a significant role in building my self-confidence and enhancing my understanding of my project.I am immensely grateful to my advisor, Dr. Sanjiv Dhingra, for his unwavering support and encouragement throughout my project. I also extend my heartfelt thanks to my labmates, colleagues at the St. Boniface Research Center, friends, and family for their assistance in overcoming my fears and instilling the confidence I needed to excel in the 3MT challenge.

Alagarsamy received $2,500 for his first place win, which was watched by over 700 people in person and online.

The event was hosted by CTVs Colleen Bready in front of a panel of esteemed UM alumni: Anita Wortzman, President, The Asper Foundation; Destiny Seymour, Founder, Indigo Arrows; and James Schellenberg, Founder & CEO, Cubresa Inc.

Every year I am impressed by the passion and poise that our graduate students bring to this amazing event, said Dr. Kelley Main, Acting Dean, Faculty of Graduate Studies. This event is such an important highlight of the work our graduate students do at UM.

Three other graduate students also received prizes in the 3MT final:

UM Retirees Association presents Akshi Malik with her second place trophy.

With one in four cancer patients developing heart failure due to chemotherapy drugs, Malik is working to eliminate this trade-off in cancer treatment. Her research focuses on understanding the mechanisms through which Doxorubicin, a chemotherapy drug, affects the hearts of cancer patients, as well as looking for a cardioprotective agent that can prevent Doxorubicin-induced heart failure.

I will forever cherish the moment when I was on stage and did my best. The happy high I felt after the talk was incomparable to any presentation I have given before. I would do it again in a heartbeat.I hope to graduate soon and work in the field of scientific outreach and communication. There is a lot of impactful research being done that the general public is not aware of and I would like to make science more accessible through my presentation skills and enthusiasm for science.

Dr. Diane Hiebert-Murphy, Provost and Vice-President (Academic) presents Shayna Giesbrecht with her third place trophy.

Giesbrechts research seeks to establish methods to use wastewater for tracking the incidence of sexually transmitted blood-borne infections, which will contribute meaningful information to infection outbreak prevention and response in the future. She was inspired by Manitoba leaders during the pandemic who put the health of Manitobans first and is driven to continue working in disease prevention at the government level helping smaller communities respond to infectious disease outbreaks.

One of my favourite things about 3MT that is not necessarily available in other research settings is getting to learn about advanced research and its impacts in really accessible language. 3MT is so audience friendly that my grandparents were able to watch online!I feel so honoured to have been chosen as the third place winner for this year. This years competition was incredibly strong, so to be chosen as a winner is a massive privilege.

Dr. Kelley Main, Acting Dean, Faculty of Graduate Studies presents Olubukola Olatosi with the Peoples Choice award.

With a greater focus on promoting early childhood oral health, Olubukolas research goal is to see a reduction in the incidence of early childhood caries among Indigenous Canadian children. Her research focuses on determining the strategies to implementing the novel Canadian Caries risk assessment tool and to provide guidelines for implementation to improve the oral health of Indigenous children.

The 3MT competition was a great experience for me, it was very competitive and I enjoyed the support from the community. This program helped me to sharpen my communication skills. It gave me a platform to disseminate my research focus.I wish to congratulate everyone who took part in this competition. I enjoyed the great support we gave each other. It was fun!

As the first place winner, Alagarsamy will go on to represent the University of Manitoba at the Western Regional 3MT Competition at the University of Saskatchewan on May 25, 2023.

Research at the University of Manitoba is partially supported by funding from the Government of Canada Research Support Fund.

 

See the article here:
UM Today | Faculty of Graduate Studies | 3MT winner is full of heart - UM Today

NANT Pediatric Cancer Consortium Spearheads Research That Identifies Targeted Therapy for High-Risk Neuroblastoma – Newswise

By Gene Therapy Clinics

Newswise It is rare that a clinical trial is changed mid-investigation. But when results are striking enough, it can occur. Such striking results have been reported in a study led by the New Approaches to Neuroblastoma (NANT) pediatric cancer consortium, which is headquartered at Childrens Hospital Los Angeles.

For patients with relapsed or refractory neuroblastoma who have an alteration in the ALK gene, lorlatinib has been shown to be a safe, effective targeted therapy. This phase 1 findingpublished today in Nature Medicineis so significant that the Childrens Oncology Group (COG) is now modifying its phase 3 protocol to replace another ALK inhibitor (crizotinib) with lorlatinib to treat newly diagnosed neuroblastoma arising from an ALK alteration.

NANT is the only clinical trials consortium focused on developing new treatments and biomarkers for children and young adults with neuroblastoma. It is an international collaboration of expert investigators from around the world working to fast-track investigation into promising new therapies to benefit young patients with neuroblastoma.

Araz Marachelian, MD, Medical Director of NANTs Operations Center and Medical Director of CHLAs Neuroblastoma MIBG Program, is the studys sponsor and co-senior author on the Nature Medicine publication.

At NANT, we are pleased to have had a leadership role in this important discovery, says Dr. Marachelian. NANTs participation included early collaboration on evaluating laboratory data, trial design, securing FDA approval and industry sponsorship, study oversight and coordination, safety monitoring, creating and maintaining the study database, and analyzing and disseminating study results.

Neuroblastoma is the third most common cancer in children and originates in the nerve cells outside the brain of infants and young children. It most commonly affects children 5 years of age or younger. Half of patients are considered to have high-risk disease and require intensive therapy that includes chemotherapy and biologic therapy, surgery, transplant, radiation and immunotherapy. Despite this multimodal approach, only 50% of high-risk patients survive.

We are thrilled to see many years of NANTs planning and operation come to fruition with the results of this important study, says Julie Park, MD, Chair of the NANT consortium. Families are urgently waiting for new treatment possibilities like this one. Dr. Park is an established neuroblastoma expert and chair of the Department of Oncology at St. Jude Childrens Research Hospital.

NANT brings together a diverse team of investigators that cannot be found at a single institution to identify promising treatment candidates, perform preclinical testing and then to design and carry out early-phase testing of these novel treatments. Because neuroblastoma is a rare disease with only 700 to 800 new cases in the U.S. each year, no single site could enroll enough patients to produce meaningful data. NANT sites enroll patients and collect consistent data that can then form the basis for a Childrens Oncology Group clinical trial and offer patients access to novel therapies across a broad geographic area in North America and Europe.

First author on the paper is Kelly C. Goldsmith of Childrens Healthcare of Atlanta and co-senior author is Yael P. Mosse of Childrens Hospital of Philadelphia. The trial was conducted at national and international sites including: Vanderbilt University Medical Center, Childrens Hospital Los Angeles, USC Keck School of Medicine, Childrens Hospital of Philadelphia, University of Iowa Hospital and Clinics, Childrens Hospital of Philadelphia, Stanford University School of Medicine, Perelman School of Medicine at the University of Pennsylvania, The Royal Marsden Hospital, London, UK, Cook Childrens Medical Center, , Department of Pediatrics, University of Chicago, Department of Pediatrics, University of Michigan, Hospital for Sick Kids, Toronto, ON, Harvard Medical School, Childrens Hospital Colorado, Seattle Childrens Hospital, Institut Curie, Paris, France and UCSF Benioff Childrens Hospital.

The study was funded by National Cancer Institute grant P01CA217959, Pfizer Inc. and other grants and foundations.

About Childrens Hospital Los Angeles Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country, and the greater Southern California region. Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in the Pacific region and California, and among the top 10 in the nation on U.S. News & World Reports Honor Roll of Best Childrens Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most advanced cases. Inclusive, kid- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC, and proven discoveries reach patients faster through The Saban Research Institute of Childrens Hospital Los Angelesamong the top 10 childrens hospitals for National Institutes of Health funding. The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the western United States. To learn more, follow us on Facebook, Instagram, LinkedIn, YouTube and Twitter, and visit our blog at CHLA.org/blog.

See the article here:
NANT Pediatric Cancer Consortium Spearheads Research That Identifies Targeted Therapy for High-Risk Neuroblastoma - Newswise

Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% – – EIN News

By Gene Therapy Clinics

Rare Neurological Disease Treatment Market -PMI

The report "Rare Neurological Disease Treatment Market, By Drug Type and By Region - Market Trends, Analysis, and Forecast till 2030

The report "Rare Neurological Disease Treatment Market, By Drug Type (Biologics and Small Molecules), By Mode of Administration (Injectables, Oral and Other Modes of Administration), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Key Highlights: In 2021, -Global Genes, a prominent international rare illness advocacy organisation, today announced the beginning of a multi-stakeholder programme called Patient Identification and Engagement for RARE CNS Disorders (PIE4CNS). The PIE4CNS initiative will address major gaps in the timely and comprehensive diagnosis of rare central nervous system (CNS)-related conditions, as well as challenges in finding and engaging patient populations in clinical research in gene therapy and other promising technologies that could lead to significant advancements in rare disease treatment.

Analyst View: The absence of appropriate therapy is the most notable driving factor for the market's main players, which will assist it develop in the forecast period's approaching years. A focus on fast-track approvals for novel and future medicines to treat such illnesses is another major element for market growth. Furthermore, recent technical breakthroughs in the fields of neurology and neurobiology have aided the growth of the global market for neurological disorder therapy. In addition, raising awareness about early detection of these conditions may aid market growth in the coming years.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4840

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Outlook for Rare Neurological Disease Treatment Strategies Key Questions this Study will Answer Market Snippet, By Drug Type Market Snippet, By Mode of Administration >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Rare Neurological Disease Treatment Market, By Drug Type, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Biologics Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Small Molecule Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 4.Global Rare Neurological Disease Treatment Market, By Mode of Administration, 2020 2030, (US$ Mn) >Overview Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Injectables Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Orals Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Global Rare Neurological Disease Treatment Market accounted for US$ 8931.49 million in 2020 and is estimated to be US$ 18367 million by 2030 and is anticipated to register a CAGR of 7.50%. The Global Rare Neurological Disease Treatment Market is segmented based on drug type, mode of administration and region. Based on Drug Type, Global Rare Neurological Disease Treatment Market is segmented into Biologics and Small Molecules. Based on Mode of Administration, Global Rare Neurological Disease Treatment Market is segmented into Injectables, Oral and Other Modes of Administration. By Region, the Global Rare Neurological Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Rare Neurological Disease Treatment Market: CSL Ltd Kedrion Biopharma Inc US WorldMeds LLC Merz Pharma GmbH & Co. KGaA Aquestive Therapeutics Inc Bayer AG Pfizer Inc Novartis AG Merck & Co. Inc. (EMD Serono Inc.) Jazz Pharmaceuticals PLC.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period

Questions answered by Rare Neurological Disease Treatment Market:

1.What is the current size of the rare neurological disease treatment market, and what are the growth projections for the market in the coming years? The current size of the rare neurological disease treatment market is estimated to be around $10 billion. The market is projected to grow at a compound annual growth rate (CAGR) of around 6% during the forecast period from 2021 to 2028, driven by factors such as increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives.

2.What are the major drivers and challenges in the rare neurological disease treatment market, and how are they impacting the growth of the market? The major drivers in the rare neurological disease treatment market include increasing prevalence of rare neurological diseases, growing investments in R&D, and favorable government initiatives. However, the market also faces challenges such as high cost of treatments, limited patient population, and difficulty in diagnosis and clinical trials. These factors can impact the growth of the market by influencing access to treatments, funding for research, and regulatory policies.

3.What are the major trends in the rare neurological disease treatment market, and how are they expected to shape the market in the future? Some of the major trends in the rare neurological disease treatment market include increasing adoption of precision medicine, growing focus on gene therapy and biologics, and development of innovative treatment approaches such as gene editing and stem cell therapy. These trends are expected to shape the market by improving treatment outcomes and expanding the range of treatment options available for rare neurological diseases. Additionally, the emergence of digital technologies such as telemedicine and wearable devices is also expected to revolutionize the way rare neurological diseases are diagnosed and treated.

Browse Other Related Research Reports from Prophecy Market Insights: Smart Pills Market: By Target Area (Small Intestine, Large intestine, Stomach, and Esophagus), By Application (Drug Delivery, Capsule Endoscopy and Others), By End-Users (Hospitals, Diagnostic Centers, Specialty Clinics and Research Institutes) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Elderly Care Market: By Product Type (Pharmaceuticals, Housing and Assistive Devices), By Service (Institutional Care, Homecare, Adult Day Care), By Application (Heart Diseases, Cancer, Kidney Diseases, Diabetes, Arthritis, Osteoporosis, Neurological, Respiratory and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+1 860-531-2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Read the rest here:
Rare Neurological Disease Treatment Market is estimated to be US$ 18367 million by 2030 with a CAGR of 7.50% - - EIN News

Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast – EIN News

By Gene Therapy Clinics

Pharmerging Market-By PMI

Pharmerging Market, By Products, By Economy , By Indication, By Distribution Channel and By Region - Trends, Analysis and Forecast till 2030

Region Analysis: The Middle East and Africa, Asia Pacific, North America, and Europe are all regions where the worldwide pharmerging market is reported to be present. In 2020, Asia Pacific dominated this market due its fast urbanization, rising patent expiration, and spike in spending in medical research, researchers. As the primary domestic market for pharmaceutical innovation in Asia Pacific, China has emerged. Europe and Latin America are projected to have strong growth in the near future, among other geographical markets for pharmerging. The Latin American healthcare industry is anticipated to grow due to technological improvements, significant research and development techniques, and rising public awareness of the administration and treatment of healthcare facilities

Key Highlights: In 2022, Saudi pharmaceutical company Jamjoom Pharma has announced the opening of a new factory in Egypt as it looks to expand its exports to newer markets in Africa. During the partnership signing event between Egypt and Saudi Arabia, the announcement was made. In 2022, Medical Marijuana, Inc., the world's first publicly traded cannabis company to introduce cannabis-derived nutraceutical products, brands, and supply chains, announced today that its first pharmaceutical subsidiary, HM Pharma, has begun operations in Brazil.

Request Free Sample: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4894

Scope of the Report: 1.Market Preview >Executive Summary >Key FindingsGlobal Pharmerging Market Key Questions this Study will Answer Market Snippet, By Product Type Market Snippet, By Economy Market Snippet, By Indication Market Snippet, By Distribution Channel Market Snippet, By Region >Opportunity Map Analysis >Executive Summary3 Big Predictions 2.Market Dynamics, Regulations, and Trends Analysis >Market Dynamics Drivers Restraints Market Opportunities Market Trends >DR Impact Analysis >PEST Analysis >Porters Five Forces Analysis >Opportunity Orbit >Market Investment Feasibility Index >Macroeconomic Factor Analysis 3.Global Pharmerging Market, By Product, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Pharmaceuticals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Healthcare Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Others Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 4.Global Pharmerging Market, By Economy , 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Tier-1 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-2 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Tier-3 Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 5.Global Pharmerging Market, By Indication, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Lifestyle Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Cancer & Autoimmune Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Infectious Disease Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 6.Global Pharmerging Market, By Distribution Channel, 2020 2030, (US$ Bn) >Overview Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 2030 Y-o-Y Growth Analysis (%), 2020 2030 Segment Trends >Hospitals Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Clinincs Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Retail Pharmacies Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >E-Commerce Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030 >Drug Stores Overview Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 2030

Key Market Insights from the report: Pharmerging Market size accounted for US$ 971.94 billion in 2020 and is estimated to be US$ 4426.72 billion by 2030 and is anticipated to register a CAGR of 16.5%. The Global Pharmerging Market is segmented based on product type, economy, indication, distribution channel and region. Based on Product Type, Pharmerging Market is segmented into Pharmaceuticals, Healthcare and Others (IT and Record Management). Based on Economy, Pharmerging Market is segmented into Tier-1, Tier-2 and Tier-3. Based on Indication, Pharmerging Market is segmented into Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease. Based on Distribution Channel, Pharmerging Market is segmented into Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores. By Region, the Pharmerging Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Pharmerging Market: Sanofi S.A. Pfizer Inc. AstraZeneca Plc GlaxoSmithKline Plc F. Hoffmann-La Roche AG (Roche AG) Eli Lilly and Company Johnson & Johnson Abbott Laboratories Novartis AG Teva Pharmaceutical Limited

Questions answered by Pharmerging Market: What are the major drivers and challenges in the pharmerging market, and how are they impacting the growth of the market? The major drivers in the pharmerging market include growing demand for healthcare services, increasing government initiatives for healthcare infrastructure development, rising disposable incomes and middle-class population, and increasing prevalence of chronic diseases. However, the market also faces challenges such as limited healthcare access in remote and rural areas, inadequate healthcare funding, lack of skilled healthcare professionals, and strict regulatory policies. These factors can impact the growth of the market by influencing the development, manufacturing, and distribution of pharmaceutical products in pharmerging markets.

What are the different types of pharmaceutical products available in the pharmerging market, and what are their applications? The different types of pharmaceutical products available in the pharmerging market include branded and generic drugs, biologics, vaccines, and medical devices. These products are used to treat a wide range of diseases and conditions, including infectious diseases, cardiovascular diseases, cancer, diabetes, and respiratory diseases. Additionally, there is an increasing focus on developing innovative therapies such as gene therapy and cell therapy to address unmet medical needs in pharmerging markets. The pharmaceutical products in pharmerging markets are often priced lower than those in developed markets to make them more affordable for the local population.

What are the major distribution channels for pharmerging market products, and how are they evolving? The major distribution channels for pharmerging market products include retail pharmacies, hospitals and clinics, e-commerce platforms, and wholesalers/distributors. In recent years, there has been a shift towards online sales of pharmaceutical products in pharmerging markets, driven by increasing internet penetration and smartphone usage. E-commerce platforms are becoming popular as they provide convenient access to a wide range of pharmaceutical products at competitive prices. Additionally, the use of mobile health (mHealth) technologies for medication management and remote monitoring is also gaining traction in pharmerging markets. However, the traditional distribution channels such as retail pharmacies and hospitals/clinics still play a significant role in the distribution of pharmaceutical products in pharmerging markets, particularly in remote and rural areas with limited internet connectivity.

Browse Other Related Research Reports from Prophecy Market Insights: Prils Market: By Type (Amipril, Quinapril, Cilazapril, Benazepril and Others), By Application (Hypertension, Heart Failure, Chronic Kidney Disorders, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Thalassemia Treatment Market: By Type (Alpha-Thalassemia and Beta-Thalassemia), By Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy and Bone Marrow Transplant), By End-User (Hospitals & Clinics, Diagnostic Laboratories and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Shweta RaskarProphecy Market Insights+ +1 860 531 2574email us hereVisit us on social media:FacebookTwitterLinkedIn

Visit link:
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast - EIN News

Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software – EIN News

By Gene Therapy Clinics

Medical Transcription Software Market

Medical transcription software converts digital voice recordings into text that will be used and accessed by medical professionals.

The software can help alleviate the workloads of physicians and ultimately prevent burnout. Nurses, physicians, and doctors dictate or feed voice recordings into the medical transcription solution and the solution produces text and reports that can be stored within a patients digital files.

: https://www.alliedmarketresearch.com/request-sample/31904#UTM_Source=EIN-Mahendra

The global medical transcription software industry generated $1.6 billion in 2021, and is anticipated to generate $7.0 billion by 2031, witnessing a CAGR of 15.5% from 2022 to 2031.

Medical transcription software has a significant scope in hospitals and clinics applications as it can help healthcare professionals streamline their documentation processes, improve accuracy, and reduce administrative workload.

:

Improved accuracy: Medical transcription software uses advanced technologies such as natural language processing and voice recognition to ensure accurate and error-free transcription of medical records.

(254 , , , ) @ https://www.alliedmarketresearch.com/medical-transcription-software-market/purchase-options#UTM_Source=EIN-Mahendra

: The software automates the transcription process, allowing healthcare professionals to save time and focus on patient care. This can result in increased productivity and reduced administrative workload.

: Medical transcription software often comes with advanced security features such as encryption, access control, and backup and recovery options, which can ensure the security and confidentiality of patient records.

: Many medical transcription software solutions can seamlessly integrate with electronic health record (EHR) systems, making it easier for healthcare professionals to access and update patient records.

: By reducing administrative workload and increasing efficiency, medical transcription software can help hospitals and clinics save on operational costs.

- https://www.alliedmarketresearch.com/purchase-enquiry/31904#UTM_Source=EIN-Mahendra

2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly two-fifths of the global medical transcription software market, and is likely to dominate the market during the forecast period. This is attributed to the surge in demand for better healthcare facilities, rise in the demand for medical transcription solution, and government reforms for the acceptance of medical transcription in the region. However, the Asia-Pacific region is expected to witness the fastest CAGR of 17.2% from 2022 to 2031. This is owing to the increase in prevalence of chronic diseases, rise in awareness related to the use of medical transcription services, and surge in healthcare expenditure.

: - 3M, Dolbey System, Inc., Global Medical Transcription, DeepScribe, Inc., Microsoft Corporation (Nuance Communication, Inc.), Amazon, Inc. (Amazon Web Services, Inc.), ZyDoc Medical Transcription, SmartMD, AQuity Solutions, iMedX.

- https://www.alliedmarketresearch.com/stem-cell-and-gene-therapy-biological-testing-market-A13443

- https://www.alliedmarketresearch.com/heart-attack-diagnostics-market-A12689

- https://www.alliedmarketresearch.com/huntington%E2%80%99s-disease-treatment-market-A17522

David CorreaAllied Analytics LLP+1 800-792-5285email us here

Original post:
Streamline Your Workflow and Boost Productivity with the Latest Medical Transcription Software - EIN News

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 … – InvestorsObserver

By Gene Therapy Clinics

Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030, Says Coherent Market Insights (CMI)

Burlingame, April 04, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global pediatric vaccines market is estimated to be valued at US$ 46,424.3 million in 202 3 and is expected to exhibit a CAGR of 5.9% during the forecast period (202 3 -2030 ).

Analysts Views on Global Pediatric Vaccines Market:

Government authorities in the India are focusing on conducting campaigns in order to provide vaccines to children, and this is expected to drive the growth of the market over the forecast period. For instance, on December 17, 2022, The Pune Municipal Corporation (PMC), India, held a special measles vaccination campaign in which 470 children in pune were immunized. Thus, increasing vaccination campaigns through government authorities can boost the market growth in near future.

Key Trends and Analysis of the Global Pediatric Vaccines Market :

Increasing vaccines approval for pediatric age group by regulatory authorities is expected to drive the market growth over the forecast period. For instance, on October 19, 2022, European Medicines Agency (EMA) recommended approval of Comirnaty and Spikevax COVID-19 vaccines for children of 6 months of age. EMAs human medicines committee (CHMP) has recommended extending the usage of Comirnaty and Spikevax that targets original strain of SARS-CoV-2. The Committee recommended usage of Comirnaty in children aged 6 months to 4 years and usage of Spikevax in children aged 6 months to 5 years. Comirnaty and Spikevax are already approved by EMA for being used in both adults and children aged from 5 and 6 years, respectively.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1708

Global Pediatric Vaccines Market - Driver s

Increasing vaccine approvals by regulatory authorities

Increasing vaccine approvals by regulatory authorities is expected to drive the Global Pediatric Vaccines Market over the forecast period. For instance, on October 15, 2021, Seqirus, a global leader in influenza prevention, and a business of CSL Limited, a biotechnology company announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine), Seqiruss cell-based quadrivalent influenza vaccine for an expanded age indication for children of age six months old. FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine, in the U.S., is now indicated for everyone that is eligible to receive an influenza vaccine in the U.S.

Market players are focused on product evaluation for pipeline product

Market players are engaged in evaluating and demonstrating safety, tolerability, and immunogenicity of vaccines, and this is expected to boost overall growth of the market. For instance, in May 2020, Sanofi, a pharmaceutical and healthcare company has initiated a Phase 2 clinical trial study of pneumococcal conjugate vaccine. Objective of this study is to evaluate immunogenicity and safety of a pneumococcal conjugate vaccine when it is administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.

Pediatric Vaccines Market Report Coverage

Global Pediatric Vaccines Market - Restrain t

Reoccurrence of adverse events after immunization

Although millions of children and adults are vaccinated in order to prevent the occurrence of infectious diseases, such as the Flu, measles, strep throat, COVID-19, and salmonella, several research studies have evaluated reoccurrence of some adverse events after influenza vaccination. Such adverse events are associated with the most common adverse reactions to live or attenuated influenza vaccine (LAIV) are runny nose or nasal congestion in all ages, fever >100F in children 2-6 years of age, and sore throat in adults. Reoccurrence of adverse events after immunization results in declining interest of people for booster dose of influenza vaccines. Therefore, such incidences can pose major challenges such as decreasing community acceptance for vaccines, and this is expected to negatively affect the pediatric vaccines market growth.

Global Pediatric Vaccines Market - Opportunity

I ncreasing government campaigns for immunization program in various region

The government authorities are focusing on the immunization programme in lower-income countries in order to provide healthcare services, and to control the prevalence rate of infectious diseases, and thus, this requires increased production of pediatric vaccines that is expected to create opportunities for market players in the development and production of pediatric vaccine. For instance, on October 28, 2022, the Global Alliance for Vaccines and Immunization (GAVI) announced that GAVI is working with governments, communities, in a concerted effort to rollout measles vaccines to vulnerable children across low income countries such as Angola, Liberia, and others. From 2022 through the first half of 2023, Gavi plans to support 22 lower-income countries to undertake measles follow-up campaigns, aiming to reach more than 85 million vaccinated children.

Global Pediatric Vaccines Market Cross Sectional Analysis:

In Vaccine Type, MMR Vaccine segment is dominant during forecast period in North America region due to increasing product approvals by regulatory authorities in the market, and this is expected to drive segment growth over the forecast period. For instance, on June 6, 2022, GSK PLC, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps, and rubella (MMR) in children of 12 months of age and older. Priorix will be available in the U.S. market.

Global Pediatric Vaccines Market Segmentation:

The Global Pediatric Vaccines Market report is segmented into Vaccine Type, Technology, Type, Distribution Channel and Region

Based on Vaccine Type , the market is segmented into Pneumococcal Vaccine, DTP Vaccine, Rotavirus Vaccine, MMR Vaccine, Polio Vaccine, Influenza Vaccine, Hepatitis B Vaccine, Meningococcal Vaccine, Hib Vaccine, and Varicella Vaccine. Out of which, pneumococcal vaccine segment is expected to dominate in global pediatric vaccines market during the forecast period, due to increasing inorganic growth strategies such as collaboration by key players in the market.

Based on Technology , the market is segmented into Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, Recombinant Vaccine. Out of which, Subunit Vaccine segment is expected to dominate in the market over the forecast period, due to increasing launches of Subunit Vaccine is expected to increase the growth of the segment over the forecast period. For instance, in 2020, Abbott, a healthcare company launched a new inactivated quadrivalent vaccine which is subunit vaccine for influenza in India.

Based on Type , the global pediatric vaccines market is segmented into Monovalent Vaccine and Multivalent Vaccine where Multivalent Vaccine segment is expected to dominate in the market over the forecast period due to prevalence of infectious disease.

Based on Distribution Channel , the global pediatric vaccines market is segmented into Government and Private. Of which, Government segment is expected to dominant in the market over the forecast period, due to increasing vaccination campaigns by government authorities.

Among all segmentation, Vaccine Type segment is expected to dominate in the market due to increasing adoption of inorganic growth strategies such as partnership by key market players in order to expand their product portfolio. For instance, in 2021, SEQIRUS., a global influenza vaccine company, announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ (Influenza A (H5N1) Monovalent Vaccine, Adjuvant), this influenza vaccine is helps in protecting individuals of six months of age and older against influenza A (H5N1) in the event of a pandemic.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1708

Global Pediatric Vaccines Market : Key Developments

In June 2022, GSK plc., a U.K.-based multinational pharmaceutical and biotechnology company, announced that the U.S. FDA has approved Priorix (Measles, Mumps, and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals of 12 months of age and older.

On June 18, 2022, the Centers for Disease Control and Prevention (CDC) has approved COVID-19 vaccination for young children of age 6 months old that means 20 million children, in the U.S., who are under 5 years are newly eligible for vaccination .

Key Market Takeaways:

Global Pediatric Vaccines Market is expected to exhibit a CAGR of 5.9% during the forecast period due to increasing effectiveness of vaccines developed by market players. For instance, in July 2021, Sanofi, a France-based multinational pharmaceutical and healthcare company, reported that its single-dose vaccine named MenQuadfi met all primary and secondary endpoints in Phase III MEQ00065 study in healthy toddlers for preventing invasive meningococcal disease (IMD), a fatal illness. The study compared the immune response against meningococcal serogroup C, and analyzed the safety of MenQuadfi in healthy toddlers aged 12 to 23 months against quadrivalent ACWY (four common types of meningococcal bacteria) vaccine, Nimenrix, and monovalent C vaccine, NeisVac-C.

Among Vaccine Type, pneumococcal vaccine segment is dominant due to increasing number of clinical trials for drug development, and this is expected to drive the segment growth over the forecast period. For instance, in April 2022, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

On the basis of Distribution Channel, government segment is expected to hold a dominant position over the forecast period, owing to increasing immunization campaigns in hospital by government authorities. For instance, on June 18, 2022, the Centers for Disease Control and Prevention (CDC) announced that all children of age 6 months to 5 years of age should receive a COVID-19 vaccine. This expands eligibility for vaccination to nearly 20 million additional children, and all Americans ages 6 months and older are now eligible for vaccination. Distribution of pediatric vaccinations for these younger children has started across the U.S. country, and will be available at thousands of pediatric practices, pharmacies, Federally Qualified Health Centers, local health departments, clinics.

Competitive Landscape:

Key players operating in the Global Pediatric Vaccines Market include GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech, and Indian Immunologicals Ltd.

Market Segmentation:

Related Market Intelligence Reports:

Plasmid DNA Manufacturing Market , By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 2030

Single-Use Bioreactor Market , By Product (Single-use Bioreactor Systems, Media Bags, Filtration Assemblies, and Other Products), By Cell Type (Mammalian Cell, Bacteria, Yeast, and Other Cell Types), By Molecule Type (Vaccines, Monoclonal Antibodies, Stem Cells, Recombinant Proteins, and Other Molecule Types), By End User (Pharmaceutical and Biopharmaceutical Industries and Contract Research Organizations (CRO) Other End Users), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter

Read the rest here:
Pediatric Vaccines Market to Surpass US$ 69,482.2 Million by 2030 ... - InvestorsObserver

→←